Altria Group, Inc. (MO): analysis and signal as of September 4, 2026

Published on September 4, 2026 at 05:19 · Updated on September 4, 2026 at 05:19 · by Aurélien Ambert, QDNA

Exchange : NYSE · Sector : Consumer Non-Durables

In short

Altria Group (ticker MO) shows a weak signal according to the verdict of 4 September 2026, with a vote of three analyses out of three. The wide regulatory moat and the gross yield of 6 % are neutralised by the absence of tobacco among the sectors favoured by the expanding macroeconomic regime and by an ambivalent technical configuration without a catalyst before the FDA decision on menthol, expected in the first quarter of 2027.

Current signal: weak (vote 3/3)
Deterministic score: +2.5 → signal expected by the scale : moderate (September 10, 2026)
Layers: fundamentals : neutral, price : neutral, risks : neutral

Triggered rules

Rule	Weight
favors a high and durable return on invested capital (ROIC), a marker of a lasting moat	+2.0
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE	-1.0
favors high gross profitability (gross profit / assets), a robust predictor of returns	+1.0
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

The weighted deterministic signal comes out at +4,00 and rests on Altria's broad regulatory competitive advantage, on a high and durable ROIC and on the defensive character of its cash flows. It is however neutralised by three sector analyses which all converge on a neutral view of listed tobacco. The gross yield of 6 %, or 4,2 % net after the 15 % US withholding and the PFU of 31,4 %, supports the stock's appeal for a yield profile, but the expanding macro regime dated 3 September 2026 favours semiconductors, artificial intelligence, electrification, energy and defensive healthcare, without including tobacco, which weighs on the revaluation potential. The technical configuration remains ambivalent: an extension of 6,8 % above the 200-session moving average, a pullback of 0,6 % below the 50-session moving average and a reversal of institutional flows over six months. No marked bullish catalyst is identified before the FDA decision on menthol, expected in the first quarter of 2027.

Bull case

The main bullish argument rests on Altria's wide regulatory moat: barriers set by the FDA, the Marlboro brand, historical market shares in the menthol segment and a near-monopoly on US distribution. These are complemented by a high and durable ROIC, a quarterly dividend held at 1,06 USD and tightened earnings guidance for the second quarter of 2026. This combination between operational quality and defensive cash flows remains rare in the event of a macroeconomic slowdown.

Bear case

The main bearish argument lies in the structural decline of US cigarette volumes, between -4 % and -5 % per year. The payout ratio exceeds 75 %, which limits the levers available in the event of a shock. No insider share acquisition has been recorded over 90 days, despite twelve Form 4 filings. The Engle progeny litigation remains permanent, the activist fund Starboard is pressing for the monetisation of the residual stakes in ABI and Cronos, and the FDA's regulatory pressure on menthol is never lifted. These factors weigh on the duration of a high-yield stock.

Scenarios

The bullish scenario, weighted at 25 %, assumes no drastic FDA decision in 2026, full maintenance of the dividend and a rotation of the market towards yield stocks in the event of a confirmed macroeconomic slowdown. The central scenario, weighted at 50 %, describes a stagnation around the current price of 69,49 USD, the capture of the 4,2 % net yield and an institutional dynamic that is degraded but not broken. The bearish scenario, weighted at 25 %, retains a menthol ban imposed by the FDA, a dividend cut, an unfavourable rotation and a rate-sensitive profile degraded by a positive US 10-2 slope.

Risks

The system retains two invalidation factors: the announcement of a dividend cut and a bearish catalyst emanating from the FDA on menthol. Either one would call into question the thesis based on the regularity of cash flows. The decline in volumes between -4 % and -5 % per year, a payout ratio above 75 %, the Engle progeny litigation and Starboard's activist pressure on the stakes in ABI and Cronos constitute the structural sources of risk that could precipitate this invalidation.

Market positioning (short sellers)

Short interest / shares outstanding: 2.43 %
Days to cover: 4.17
Settlement date: 2026-08-14
Source: FINRA (disseminated on 2026-08-26)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Signal history (last 12 months)

Date	Signal	New fact
September 4, 2026	weak (3/3)	First verdict delivered on this stock, no earlier point of comparison is available.

Frequently asked questions

Why is the published signal weak despite a gross yield of 6 %?

The signal is weak because the stock's strengths, its regulatory moat and its yield, are neutralised by an unfavourable environment. The expanding macroeconomic regime dated 3 September 2026 favours semiconductors, artificial intelligence, electrification, energy and defensive healthcare, without tobacco. The technical configuration remains ambivalent and no bullish catalyst is identified before the FDA decision on menthol, expected in the first quarter of 2027.

What does the FDA decision on menthol represent for the stock?

This decision is the main identified catalyst, expected in the first quarter of 2027. A ban would strike the group's historical market shares in the menthol segment and feeds the bearish scenario, weighted at 25 %, which incorporates a dividend cut. The absence of a drastic measure in 2026 would support the bullish scenario, weighted at 25 %, with a fully maintained dividend.

What yield does the dividend provide after taxation?

The stock shows a gross yield of 6 %. After the 15 % US withholding tax and the 31,4 % single flat tax, the net yield comes out at 4,2 %. The quarterly dividend is held at 1,06 USD. The payout ratio however exceeds 75 % of earnings, which limits the room for manoeuvre in the event of a shock to the business.

What litigation and shareholder pressures weigh on the stock?

The Engle progeny litigation constitutes a permanent burden for the group. The activist fund Starboard is exerting pressure for the monetisation of the residual stakes in ABI and Cronos. Also noted are twelve Form 4 filings and no insider share acquisition over 90 days, an unfavourable indicator as to the executives' internal conviction about the stock.

What do the technical indicators show?

Over the long term, the price trades above its 200-session moving average, with an extension of 6,8 %. Over the short term, it sits below its 50-session moving average, with a pullback of 0,6 %. Institutional flows have reversed over six months. This combination reflects an ambivalent configuration, without a dominant trend.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

August 28, 2026 — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; 7.01 Reg… (SEC · 8-K)
July 30, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
July 30, 2026 — 10-Q (SEC · 10-Q)
May 18, 2026 — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; 5.07 Sub… (SEC · 8-K)
April 30, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 4, 2026; this page was completed on September 4, 2026 at 05:19 (UTC).
Interests: no position in the stock analysed (MO) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.